Navigation Links
Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
Date:10/23/2007

SUNNYVALE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) will announce financial results for the third quarter of 2007 after the markets close on Thursday, Nov. 1, 2007. The announcement will be followed by a live conference call and webcast that afternoon at 4:30 p.m. Eastern Time.

CEO John Bishop and Senior V.P. and CFO John Sluis will host the conference call to discuss Cepheid's financial results and business highlights. Interested participants and investors may access the teleconference call by dialing 866-713-8564 (U.S./Canada) or 617-597-5312 (international), participant code 54436442. A telephonic replay will be available for seven days beginning at 6:30 p.m. Eastern Time. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 20626524.

The webcast of the call can be accessed on the Investor section of Cepheid's Web site at http://www.cepheid.com. Web participants are encouraged to go to the Web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. After the live webcast, a replay will remain available in the Investors section of Cepheid's Web site for 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.


'/>"/>
SOURCE Cepheid
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Shorter Radiation Schedules Found To Be More Effective For Patients With Breast Cancer
2. Vaccination Schedules Rates among Canadian Kids Dip Low
3. UP Government Fixes Work Schedules for Provincial Medical Service Doctors
4. Third artificial heart patient introduced
5. Extra hormone found to cut appetite by a third
6. Third generation Small pox vaccine from Cell-culture
7. Surgery Offers Better Treatment For Third Degree Piles
8. One Third Of All Cancers Preventable!
9. Britain Announces Third Transfusion Related Mad Cow Case
10. Kleins Third Way Has Tough Opposition
11. Ignorance about AIDS rampart in Third of College Students: Chinese survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
Breaking Medicine Technology: